Across the pharmaceutical supply chain, the amount patients ultimately pay for a given drug can run well above what that same medication cost to acquire. Questions around drug pricing — specifically the width of profit margins and whether patients can realistically afford the medicines they need — have been thrust into the spotlight by a recent observation from the Supreme Court.
A Public Interest Litigation hearing brought the Supreme Court's attention to pharmaceutical pricing methods, with the bench conveying pointed displeasure and characterising the approach as tantamount to open theft from consumers. Buyers of prescription medicines frequently have no way of knowing what those medicines actually cost, the court found, a gap in transparency that leaves them open to paying more than they should.
The bench anchored its reasoning in a specific drug whose market price of Rs 27,000 runs at roughly ten times the Rs 2,700 figure cited in available reports. A gap of tenfold separates the two figures. Pricing gaps tied to heart stents and antibiotics also drew attention during the proceedings.
Among those most affected are people undergoing cancer treatment, whose households often absorb the steep out-of-pocket costs tied to their medications. Judges hearing the case raised doubts about whether protections already in place were doing enough to stop profit margins on medicines and medical products from climbing beyond reasonable bounds.
A cap of 30 per cent on profit margins for cancer drugs was put in place by the federal government after the judiciary raised concerns about pricing. The Supreme Court determined that limiting price-margin controls to cancer drugs alone fell short of what is needed. Under the DPCO-2013 framework, the query arose as to why its provisions had not been extended more broadly to place a ceiling — set at 16 per cent — on the margins that retailers are permitted to collect on other essential medicines and medical devices.
Questions about medicine affordability and whether tighter regulatory frameworks could shield patients from elevated drug costs have resurfaced, drawing attention at a time when those affected are simultaneously managing health conditions. One voice in the discussion noted that treatment access remains a basic necessity for maintaining wellbeing.
Mamata Behera, a buyer from Cuttack, told a broadcaster that everyday ailments — digestive disorders, acidity, diabetes, and hypertension — are now touching a growing number of households. She added that a range of medicines, cancer treatments in particular, remain outside the Drug Price Control Order and, in her view, ought to be brought within its coverage. Prices for these items sit at the upper end of the market, and their maximum retail values differ noticeably from one product to the next.
Bhagabat Prasad Sahu, who heads the Cuttack district drug traders' association, expressed the view that people undergoing cancer treatment — a condition where the stakes for survival are high — deserve protection from pricing practices that take undue advantage of their circumstances.
